

# Functional dyspepsia in adults

**Authors:** [George F Longstreth, MD](#), [Brian E Lacy, MD, PhD](#)

**Section Editor:** [Nicholas J Talley, MD, PhD](#)

**Deputy Editor:** [Shilpa Grover, MD, MPH, AGAF](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

**Literature review current through:** Jun 2020. | **This topic last updated:** Dec 16, 2019.

---

## INTRODUCTION

Dyspepsia is a common symptom with an extensive differential diagnosis and a heterogeneous pathophysiology [1]. The prevalence of uninvestigated dyspepsia worldwide is about 20 percent, especially in women, smokers, and people taking nonsteroidal anti-inflammatory agents. The prevalence varies according to the definition used for dyspepsia [2,3]. Dyspepsia can significantly impair quality of life [4]. The proportion of affected people who seek medical care ranges from 14 to 66 percent in various countries and ethnic groups [5]. The majority of patients (75 to 80 percent) with symptoms of dyspepsia are eventually categorized as having functional (idiopathic, nonulcer) dyspepsia. This topic review will provide an overview of the pathophysiology and treatment of functional dyspepsia.

Our recommendations for the diagnosis and management of functional dyspepsia are largely consistent with the American College of Gastroenterology and American Gastroenterological Association guidelines [6,7]. The etiology, general approach to the evaluation, and management of the patient with uninvestigated dyspepsia are presented separately. (See "[Approach to the adult with dyspepsia](#)".)

---

## EPIDEMIOLOGY AND PATHOPHYSIOLOGY

The prevalence of functional dyspepsia ranges from 5 to 11 percent worldwide [2,3]. The pathophysiology of functional dyspepsia is not well understood. However, several potential mechanisms have been suggested. These mechanisms may differ between subtypes of functional dyspepsia (postprandial distress syndrome and epigastric pain syndrome) [8]. (See

['Diagnostic criteria'](#) below.)

- **Gastric motility and compliance** – Functional dyspepsia has been associated with several motility disorders. These include mild delays in gastric emptying, rapid gastric emptying, antral hypomotility, gastric dysrhythmias, and impaired gastric accommodation in response to a meal [8-10]. However, these findings are noted in only a subset of patients with dyspepsia. As examples, delayed gastric emptying and antral hypomotility are found in approximately 25 to 35 percent of patients with dyspepsia while up to 10 percent of patients with dyspepsia have rapid gastric emptying [11-14]. (See "[Gastroparesis: Etiology, clinical manifestations, and diagnosis](#)".)
- **Visceral hypersensitivity** – Visceral hypersensitivity is characterized by a lowered threshold for induction of pain in the presence of normal gastric compliance. Visceral hypersensitivity independent of delayed gastric emptying has been demonstrated in patients with functional dyspepsia [15-18]. Both mechanoreceptor dysfunction and aberrant processing of afferent input in the spinal cord or brain may play a role in the pathophysiology of visceral hypersensitivity [19]. In one study that included 270 patients with functional dyspepsia, 37 percent had hypersensitivity to gastric distension, and hypersensitive patients reported higher cumulative symptom scores as compared with normosensitive patients [8]. In another study, intragastric acid infusion in 23 functional dyspepsia patients and 32 healthy controls elicited dyspeptic symptoms in a greater proportion of dyspepsia patients [20].
- ***Helicobacter pylori* infection** – Although there are several hypotheses with regard to the role of *Helicobacter pylori* infection in the pathogenesis of functional dyspepsia, the mechanism remains unclear. *H. pylori* may cause smooth muscle dysfunction due to the induction of an inflammatory response or by the initiation of an antibody response [21,22]. However, studies have not found an association between *H. pylori* and abnormal gastric motor function in patients with functional dyspepsia [23]. (See "[Pathophysiology of and immune response to Helicobacter pylori infection](#)".)

The inflammatory response induced by *H. pylori* may lower the discomfort threshold to gastric distension by causing alterations in the enteric or central nervous system [24]. However, in at least one study, *H. pylori* positive and negative patients with functional dyspepsia had no difference in the perception of mechanically-induced gastric distension [25].

There is evidence from randomized controlled trials that eradication of *H. pylori* results in relief of dyspepsia in only a minority of patients. However, studies have failed to establish a

temporal relationship between *H. pylori* infection and functional dyspepsia, or the association of *H. pylori* with a specific symptom complex [24]. Therefore, relief of dyspepsia may reflect other factors such as cure of unrecognized peptic ulcer disease in patients misdiagnosed with functional (nonulcer) dyspepsia, alterations in acid secretion, or changes in the gut microbiota.

- **Altered gut microbiome** – Alterations in the upper gastrointestinal tract microbiome may result in the development of dyspepsia. This hypothesis is supported by the observation that dyspeptic symptoms are more likely to occur after an episode of gastroenteritis [26-29]. In one study, risk factors for the persistence of dyspepsia eight years after exposure to a waterborne outbreak of bacterial dysentery were female sex, smoking, premorbid irritable bowel syndrome, anxiety, depression, and >7 days of diarrhea or abdominal cramps during the acute illness [27]. It has also been hypothesized that the efficacy of *H. pylori* therapy in improving symptoms of functional dyspepsia is due to the impact on the gut microbiome rather than the eradication of *H. pylori* alone [30,31].
- **Duodenal inflammation** – An association between functional dyspepsia and increased duodenal eosinophilia has been reported, with an increase in duodenal eosinophils in patients with early satiety [32-34]. Increased eosinophil degranulation and mast cell hyperplasia has also been reported [35,36]. However, lower levels of duodenal eosinophilia can occur in a healthy population [37,38]. One study noted both structural and functional differences in duodenal submucous ganglia between patients with functional dyspepsia and controls [39].
- **Psychosocial dysfunction** – Functional dyspepsia may result from a complex interaction of psychosocial and physiological factors. Dyspepsia has been associated with generalized anxiety disorder, somatization, and major depression [11,40-43]. There is also a higher prevalence of functional gastrointestinal disorders in patients with self-reported history of childhood abuse [44,45].

---

## CLINICAL MANIFESTATIONS

Patients with functional dyspepsia usually describe postprandial fullness, early satiety, bloating and/or epigastric pain/burning. Postprandial fullness is the most intense symptom in patients with meal-induced symptoms [46]. Symptoms may be severe enough to limit usual activities. Some patients may have nausea, vomiting, or heartburn, however, these symptoms are usually infrequent.

---

## DIAGNOSIS

**Overview of diagnostic approach** — Functional dyspepsia is suspected in patients with a clinical history of postprandial fullness, early satiety, or epigastric pain/burning. A clinical diagnosis of functional dyspepsia requires the fulfillment of symptom-based diagnostic criteria and an evaluation to exclude other causes of dyspepsia. This evaluation consists of a history (eg, dietary, medical, surgical, family, and medications/supplements), physical examination, laboratory studies, and endoscopic evaluation to exclude organic/structural disease to explain the symptoms ([algorithm 1](#)). An approach to the evaluation of a patient with dyspepsia is discussed in detail separately. (See "[Approach to the adult with dyspepsia](#)", section on 'Initial evaluation' and "[Approach to the adult with dyspepsia](#)", section on 'Diagnostic strategies and initial management'.)

**Diagnostic criteria** — Symptom-based criteria have been proposed to standardize the diagnosis of functional dyspepsia.

- **Rome IV criteria for functional dyspepsia** – According to the Rome IV criteria, functional dyspepsia is defined as the presence of one or more of the following symptoms: postprandial fullness, early satiation, epigastric pain or epigastric burning, and no evidence of structural disease (including at upper endoscopy) to explain the symptoms ([table 1](#)) [47].

While patients with these symptoms and a negative diagnostic evaluation likely have functional dyspepsia, according to the Rome IV guidelines, the criteria should be fulfilled for the last three months with symptom onset at least six months before diagnosis. Criteria for symptom frequency and duration are particularly useful in defining patient eligibility for research, but clinician judgement may allow diagnosis in practice without rigid adherence to them.

- **Functional dyspepsia subtypes** – Two subtypes of functional dyspepsia are recognized based on the predominant symptoms. However, overlap between these subtypes is common [8,48].
  - Postprandial distress syndrome is characterized by bothersome postprandial fullness and/or early satiation ([table 1](#)).
  - Epigastric pain syndrome is characterized by bothersome epigastric pain or burning that is not exclusively postprandial ([table 1](#)).

---

## DIFFERENTIAL DIAGNOSIS

The differential diagnosis of functional dyspepsia includes other organic causes of dyspepsia ([table 2](#)). Although there are several organic causes for dyspepsia, the main causes are peptic ulcer disease, gastritis, gastroesophageal reflux, and medications (eg, nonsteroidal anti-inflammatory drugs [NSAIDs]). An underlying gastric malignancy is a rare cause of dyspepsia in North America. Functional dyspepsia is differentiated from these by clinical assessment, laboratory testing, and upper endoscopy. (See ["Approach to the adult with dyspepsia", section on 'Dyspepsia secondary to organic disease'](#).)

- **Gastroesophageal reflux disease** – The most common symptoms of gastroesophageal reflux disease are retrosternal burning pain and regurgitation. Dyspepsia symptoms can coexist with heartburn, but in patients with functional dyspepsia, epigastric pain, and fullness are the predominant symptoms [\[49\]](#).
- **Gastroparesis** – Gastroparesis is less prevalent than functional dyspepsia, but overlaps with it, as gastric emptying may be slow and symptoms of dyspepsia occur in both disorders [\[50,51\]](#). Patients with functional dyspepsia may have nausea. However, in patients with gastroparesis, vomiting, rather than abdominal pain or epigastric fullness, is generally the predominant symptom.
- **Irritable bowel syndrome** – More than 60 percent of patients with functional dyspepsia may have overlapping irritable bowel syndrome symptoms [\[1,7,47\]](#), and the overlap may be more likely when the symptoms of either disorder are severe [\[52\]](#). Rather than epigastric pain associated with functional dyspepsia, irritable bowel syndrome is characterized by abdominal pain or discomfort associated with a change in stool form or frequency. As compared with patients with irritable bowel syndrome alone, patients with both irritable bowel syndrome and functional dyspepsia had increased bloating and abdominal pain after a lactulose-nutrient challenge test [\[53\]](#).

---

## MANAGEMENT

The management of patients with functional dyspepsia is controversial and alleviates symptoms in only a small proportion of patients ([algorithm 1](#)) [\[47,54\]](#).

**Initial approach** — Patients with functional dyspepsia should be tested and treated for *Helicobacter pylori*. We treat patients with functional dyspepsia who test negative for *H. pylori* and those with persistent symptoms four weeks after eradication of *H. pylori* with a proton pump inhibitor (PPI). However, approximately 90 percent of patients will continue to have symptoms despite PPI therapy and require additional treatment. (See ['Helicobacter pylori test and treat'](#)

below and ['Proton pump inhibitors'](#) below and ['Subsequent approach'](#) below.)

**Helicobacter pylori test and treat** — The diagnosis of *H. pylori* should be made with a test for active infection (stool antigen assay or urea breath test) if testing was not performed at the time of upper endoscopy performed for evaluation of dyspepsia ([algorithm 1](#)). Serologic testing should not be performed due to the low positive predictive value. (See ["Indications and diagnostic tests for Helicobacter pylori infection"](#), [section on 'Approach to diagnostic testing'](#) and ["Approach to the adult with dyspepsia"](#), [section on 'Diagnostic strategies and initial management'](#).)

*H. pylori* eradication may improve dyspeptic symptoms by altering acid secretion or modification of intestinal microbiota [[55,56](#)]. It also has the benefit of preventing unrecognized peptic ulcers associated with *H. pylori*. A systematic review of 22 randomized controlled trials included 4896 patients with functional dyspepsia and *H. pylori* who were treated with eradication therapy or placebo. Eradication of *H. pylori* was associated with a small but significant benefit in relieving functional dyspepsia, with treatment of 13 patients needed to cure one case of functional dyspepsia (RR persistent dyspepsia 0.91, 95% CI 0.88-0.94) [[56,57](#)]. (See ["Treatment regimens for Helicobacter pylori"](#) and ['Epidemiology and pathophysiology'](#) above.)

**Proton pump inhibitors** — PPIs appear to be moderately effective in the treatment of some patients with functional dyspepsia. In a systematic review of 18 randomized controlled trials, PPIs were more effective than placebo in relieving overall dyspepsia symptoms (RR 0.88, 95% CI 0.82-0.94) with a NNT of 11 [[58](#)]. Low- and standard-dose PPIs had similar effectiveness. In patients with functional dyspepsia who respond to PPI therapy, attempts should be made to discontinue PPIs every 6 to 12 months to minimize long-term risk of therapy.

**H2-receptor antagonists** — In a meta-analysis of 12 trials with a total of 2183 patients, H2RAs were associated with a 23 percent reduction in symptoms compared with placebo (RRR 23 percent, 95% CI 8-35 percent) with a NNT of 7 [[59](#)]. In the systematic review of PPI therapy for functional dyspepsia, only two studies compared the efficacy of PPIs with H2AAs, and no difference was evident [[58](#)]. However, the quality of most trials included was poor, and there was significant heterogeneity among studies. Another limitation of these studies is that patients with gastroesophageal reflux disease may have been misclassified as having functional dyspepsia.

## Subsequent approach

**Antidepressants** — Central mechanisms may contribute to functional dyspepsia either through increased upper gastrointestinal sensitivity or through other mechanisms. In patients

with functional dyspepsia whose symptoms do not improve after eight weeks of PPI therapy, we initiate a therapeutic trial with a tricyclic antidepressant. For patients with a partial clinical response to a PPI, a tricyclic antidepressant can be initiated as combination therapy. For patients who fail to improve on a PPI, the PPI should be stopped and a tricyclic antidepressant initiated.

We begin with a TCA at a low dose (eg, [amitriptyline](#) 10 mg or [desipramine](#) 25 mg at night). The dose may be increased at two-week intervals. A dose of 20 to 30 mg is adequate in many patients, and we do not exceed a dose of 75 mg in most patients. Higher doses may not be more effective than lower doses and may be associated with daytime sedation and other anticholinergic side effects. We usually continue the TCA for 8 to 12 weeks before stopping, if it is ineffective. If the patient responds, we usually continue the drug for appropriately six months and then consider slowly tapering the medication off. The TCA can be resumed if dyspepsia recurs. While some clinicians prefer to use [trazodone](#) rather than amitriptyline or desipramine, there are few clinical data to support its use. Low dose TCAs may also improve associated symptoms of insomnia and fibromyalgia in patients with functional dyspepsia [[60,61](#)].

In a meta-analysis of antidepressant therapy clinical trials, sub-group analysis of four trials of tricyclic agents revealed the agents were associated with reduced numbers of patients who were unimproved compared with placebo (RR = 0.76, 95% CI 0.62-0.94) [[62](#)]. In contrast, sub-group analysis of two studies of selective serotonin reuptake inhibitors did not show benefit. In a subsequent randomized trial, 107 patients with functional dyspepsia refractory to PPI therapy and prokinetics were assigned to low dose [imipramine](#) (50 mg daily) or placebo for 12 weeks [[63,64](#)]. At 12 weeks, relief of global dyspepsia symptoms occurred in a significantly higher proportion of patients on imipramine as compared with placebo (64 versus 37 percent). However, adverse effects were more common in patients on imipramine.

[Mirtazapine](#) has also demonstrated benefit in patients with functional dyspepsia and unintentional weight loss that may be due to a central mechanism of action [[65-67](#)]. In 34 patients with >10 percent weight loss randomized to mirtazapine 15 mg per day or placebo for eight weeks, mirtazapine reduced global symptoms of dyspepsia, early satiation, and gastrointestinal-specific anxiety. In addition, patients treated with mirtazapine reported improved nutrient tolerance and quality of life and weight gain [[65](#)]. In another study in which 60 patients with functional dyspepsia and >5 percent weight loss randomized to mirtazapine 30 mg per day, [paroxetine](#) 20 mg per day or conventional (acid inhibitor or prokinetic) therapy for eight weeks, mirtazapine reduced dyspepsia and depression and resulted in weight gain compared with the other two groups [[66](#)]. Mirtazapine-associated drowsiness was common in both studies.

**Prokinetic agents** — We reserve the use of prokinetics (eg, [metoclopramide](#) 5 to 10 mg

three times daily one-half an hour before meals and at night for four weeks), to patients in whom other therapies have failed and limit their duration to four weeks before discontinuing treatment [7]. If symptoms recur, we repeat a course of therapy, recognizing that up to 30 percent of patients may have side effects, most of which are generally mild and resolve with cessation of therapy [7].

In a systematic review and meta-analysis that included 29 trials of six individual agents (cisapride, acotiamide, itopride, [tegaserod](#), mosapride, and ABT-229) in patients with functional dyspepsia, overall, global symptom improvement was greater with individual agents than placebo (40 versus 26 percent, respectively) [68]. Furthermore, the quality of evidence, according to the GRADE system, was very low. Comparisons of [domperidone](#) versus newer prokinetics revealed no superiority, also with a very low quality of evidence. No improvement in quality of life was documented. All agents were well tolerated over a short term except cisapride. Few studies related efficacy to gastric emptying data, providing no support for assessing gastric emptying to direct therapy. Notably, no eligible studies assessed [metoclopramide](#) or domperidone, the only agents available in North America, in functional dyspepsia.

If postprandial nausea is a predominant symptom, trials of other antiemetic agents can be employed (eg, [promethazine](#), [prochlorperazine](#), [meclizine](#)), although data from clinical trials are lacking.

---

## THERAPIES WITH LIMITED OR UNCLEAR ROLE

- **Psychotherapy** – We reserve psychotherapy in motivated patients who associate symptoms with stressors and in patients who fail initial empiric medical therapy. The psychological factors associated with functional dyspepsia suggest that psychological therapy could help some patients. A systematic review of four trials (relaxation therapy and hypnosis, psychodrama, psychotherapy, and cognitive-behavioral therapy) suggested therapy could be beneficial for one year, but methodological deficiencies led to uncertainty about the results [69]. (See "[Overview of psychotherapies](#)", [section on 'Cognitive and behavioral therapies'](#).)
- **Fundic relaxant drugs** – There is limited evidence that relaxing the gastric fundus may improve early satiation and postprandial fullness. In a small randomized trial, [buspirone](#) (10 mg, three times daily for four weeks) as compared with placebo increased gastric accommodation and reduced the overall severity of symptoms of dyspepsia, despite slowing gastric emptying of liquids [70]. In another study that included 32 patients with



functional dyspepsia refractory to PPIs and/or [domperidone](#), buspirone improved gastric emptying measured by  $^{13}\text{C}$ -octanoic breath test and reduced early satiation [71].

- **Antinociceptive agents** – It is hypothesized that antinociceptive agents (eg, [carbamazepine](#), [tramadol](#), or [pregabalin](#)) may impact the central processing of pain, thereby decreasing visceral hypersensitivity that has been associated with functional dyspepsia. A post hoc analysis of data obtained from six randomized controlled trials in patients with generalized anxiety disorder and prominent gastrointestinal symptoms showed that pregabalin was significantly more effective than placebo in treating both anxiety and gastrointestinal symptoms [72]. In a placebo-controlled trial of pregabalin in patients with irritable bowel syndrome reduced pain, but adequate relief did not differ from the placebo group [73]. However, results of trials in functional dyspepsia are needed. We do not routinely use of tramadol for the treatment of functional gastrointestinal disorders due to the potential for addiction.
- **Complementary and alternative medicine** – Several complementary and alternative medicine approaches to functional dyspepsia have been described. However, further studies are needed before they can be recommended [74,75]. A systematic review of several low quality studies involving herbal and natural products, acupuncture, and homeopathy suggested a benefit from peppermint oil and STW5, a European multiherbal preparation that includes peppermint and caraway [76]. STW5 may improve symptoms of functional dyspepsia by stimulating gastric fundic relaxation and antral motility [77]. An eight-week placebo-controlled trial of STW5 found statistically significant but marginal symptomatic improvement [78]. A study in 95 patients with FD (Rome III criteria) found that a combination of L-menthol and caraway oil improved postprandial FD symptoms in some patients [79].
- **Dietary modification** – Controlled dietary studies are difficult to conduct, but there are limited data to support dietary modification [80]. A population case–control study failed to find an association between various foods and functional gastrointestinal disorders [81], but a review of 16 studies revealed dyspepsia induction by some foods, including wheat, dietary fat, and caffeine [80].

---

## ADDITIONAL EVALUATION OF PERSISTENT SYMPTOMS

Patients with functional dyspepsia who have persistent symptoms of dyspepsia may require additional testing for an alternate diagnosis. We perform a gastric emptying study to evaluate for gastroparesis in selected patients with refractory functional dyspepsia who have persistent

nausea and vomiting or risk factors for delayed gastric emptying (eg, diabetes mellitus). Delayed gastric emptying has been found in approximately 30 percent of patients complaining of dyspeptic symptoms. However, it is important that a significant overlap exists between dyspepsia and gastroparesis [50,51]; and treatment directed at accelerating delayed gastric emptying in these patients may not necessarily improve symptoms. (See "[Gastroparesis: Etiology, clinical manifestations, and diagnosis](#)", section on 'Evaluation' and "[Treatment of gastroparesis](#)".)

---

## PROGNOSIS

Functional dyspepsia has a chronic disease course with symptoms that vary in severity over time [1]. Patients may be asymptomatic for periods of time and have periodic symptomatic relapses. In two population-based studies of the natural history of functional dyspepsia, over a follow-up of 10 to 12 years approximately 15 to 20 percent of individuals had persistent symptoms and 40 to 52 percent had symptom resolution [82]. In 30 to 35 percent of patients symptoms fluctuated over time and patients met criteria for another functional gastrointestinal disorder.

**SOCIETY GUIDELINE LINKS** — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "[Society guideline links: Dyspepsia](#)".)

---

## INFORMATION FOR PATIENTS

UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

- Basics topics (see "[Patient education: Stomach ache and stomach upset \(The Basics\)](#)")

- Beyond the Basics topics (see "[Patient education: Upset stomach \(functional dyspepsia\) in adults \(Beyond the Basics\)](#)")
- 

## SUMMARY AND RECOMMENDATIONS

- The prevalence of functional dyspepsia is about 20 percent worldwide. The pathophysiology of functional dyspepsia is not well understood. Several potential mechanisms have been suggested. (See '[Epidemiology and pathophysiology](#)' above.)
- Patients with functional dyspepsia describe postprandial fullness, early satiety, and/or epigastric pain/ burning. Nausea, vomiting, or heartburn are less frequent. (See '[Epidemiology and pathophysiology](#)' above and '[Clinical manifestations](#)' above.)
- A clinical diagnosis of functional dyspepsia requires the fulfillment of symptom-based diagnostic criteria and an evaluation to exclude other causes of dyspepsia ([algorithm 1](#) and [table 1](#)). This evaluation consists of a history, physical examination, laboratory studies, and endoscopic evaluation to exclude organic/structural disease underlying the symptoms. The evaluation of a patient with dyspepsia to establish the cause is discussed in detail, separately. (See "[Approach to the adult with dyspepsia](#)".)
- Non-invasive testing for active *Helicobacter pylori* (*H. pylori*) infection should be performed in patients with functional dyspepsia if gastric biopsies were not obtained for *H. pylori* on upper endoscopy ([algorithm 1](#)). We suggest treatment for *H. pylori* in patients with functional dyspepsia who test positive for an infection (**Grade 2A**). (See "[Treatment regimens for Helicobacter pylori](#)".)
- We suggest a four- to eight-week trial of a once daily proton pump inhibitor (PPI) in patients with functional dyspepsia and no evidence of *H. pylori* and patients with persistent symptoms after eradication of *H. pylori* (**Grade 2A**). (See '[Proton pump inhibitors](#)' above.)
- We suggest a tricyclic antidepressant drug for patients with persistent symptoms after an eight-week trial of a PPI (**Grade 2C**). We start with a low dose (eg, [amitriptyline](#) 10 mg at bedtime or [desipramine](#) 25 mg at bedtime) and gradually increase the dose as tolerated. (See '[Antidepressants](#)' above.)
- We suggest the use of prokinetics in patients in whom eradication of *H. pylori* and a trial of proton pump inhibitor and tricyclic antidepressant has failed (**Grade 2C**). In such patients, we generally limit a trial of [metoclopramide](#) to 5 to 10 mg three times daily one-half an hour before meals and at night for about four weeks. The risk of side effects, including tardive

dyskinesia, increase with the cumulative dose and duration of treatment. We refer motivated patients who fail medical therapy and patients who associate symptoms with stressors for psychotherapy. (See ['Prokinetic agents'](#) above.)

- Functional dyspepsia has a chronic disease course with symptoms that vary in severity over time. Patients may be asymptomatic for periods of time followed by symptomatic relapses. (See ['Prognosis'](#) above.)

Use of UpToDate is subject to the [Subscription and License Agreement](#).

---

## REFERENCES

1. [Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med 2015; 373:1853.](#)
2. [Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015; 64:1049.](#)
3. [Aziz I, Palsson OS, Törnblom H, et al. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol 2018; 3:252.](#)
4. [Hantoro IF, Syam AF, Mudjaddid E, et al. Factors associated with health-related quality of life in patients with functional dyspepsia. Health Qual Life Outcomes 2018; 16:83.](#)
5. [Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am J Gastroenterol 2001; 96:1340.](#)
6. [Talley NJ, American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129:1753.](#)
7. [Moayyedi P, Lacy BE, Andrews CN, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol 2017; 112:988.](#)
8. [Vanheel H, Carbone F, Valvekens L, et al. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. Am J Gastroenterol 2017; 112:132.](#)

9. [Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. \*Gastroenterology\* 2006; 130:296.](#)
10. [Ly HG, Weltens N, Tack J, Van Oudenhove L. Acute Anxiety and Anxiety Disorders Are Associated With Impaired Gastric Accommodation in Patients With Functional Dyspepsia. \*Clin Gastroenterol Hepatol\* 2015; 13:1584.](#)
11. [Scolapio JS, Camilleri M. Nonulcer dyspepsia. \*Gastroenterologist\* 1996; 4:13.](#)
12. [Koch KL, Stern RM. Functional disorders of the stomach. \*Semin Gastrointest Dis\* 1996; 7:185.](#)
13. [Quarero AO, de Wit NJ, Lodder AC, et al. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. \*Dig Dis Sci\* 1998; 43:2028.](#)
14. [Delgado-Aros S, Camilleri M, Cremonini F, et al. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. \*Gastroenterology\* 2004; 127:1685.](#)
15. [Mertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. \*Gut\* 1998; 42:814.](#)
16. [Samsom M, Verhagen MA, vanBerge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. \*Gastroenterology\* 1999; 116:515.](#)
17. [Camilleri M, Malagelada JR, Kao PC, Zinsmeister AR. Gastric and autonomic responses to stress in functional dyspepsia. \*Dig Dis Sci\* 1986; 31:1169.](#)
18. [Farré R, Vanheel H, Vanuytsel T, et al. In functional dyspepsia, hypersensitivity to postprandial distention correlates with meal-related symptom severity. \*Gastroenterology\* 2013; 145:566.](#)
19. [Van Oudenhove L, Vandenberghe J, Dupont P, et al. Abnormal regional brain activity during rest and \(anticipated\) gastric distension in functional dyspepsia and the role of anxiety: a H\(2\)\(15\)O-PET study. \*Am J Gastroenterol\* 2010; 105:913.](#)
20. [Oshima T, Okugawa T, Tomita T, et al. Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjects. \*Aliment Pharmacol Ther\* 2012; 35:175.](#)

21. [Bercík P, De Giorgio R, Blennerhassett P, et al. Immune-mediated neural dysfunction in a murine model of chronic Helicobacter pylori infection. Gastroenterology 2002; 123:1205.](#)
22. [Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013; 10:168.](#)
23. [Minocha A, Mokshagundam S, Gallo SH, Rahal PS. Alterations in upper gastrointestinal motility in Helicobacter pylori-positive nonulcer dyspepsia. Am J Gastroenterol 1994; 89:1797.](#)
24. [Talley NJ, Hunt RH. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology 1997; 113:S67.](#)
25. [Mearin F, de Ribot X, Balboa A, et al. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995; 37:47.](#)
26. [Mearin F, Pérez-Oliveras M, Perelló A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129:98.](#)
27. [Ford AC, Thabane M, Collins SM, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 2010; 138:1727.](#)
28. [Pike BL, Porter CK, Sorrell TJ, Riddle MS. Acute gastroenteritis and the risk of functional dyspepsia: a systematic review and meta-analysis. Am J Gastroenterol 2013; 108:1558.](#)
29. [Rahman MM, Ghoshal UC, Sultana S, et al. Long-Term Gastrointestinal Consequences are Frequent Following Sporadic Acute Infectious Diarrhea in a Tropical Country: A Prospective Cohort Study. Am J Gastroenterol 2018; 113:1363.](#)
30. [Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: what are we treating?: comment on "Helicobacter pylori eradication in functional dyspepsia". Arch Intern Med 2011; 171:1936.](#)
31. [Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut 2017; 66:1168.](#)
32. [Talley NJ, Walker MM, Aro P, et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol 2007;](#)

33. Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther 2009; 29:765.
34. Walker MM, Talley NJ. Clinical value of duodenal biopsies--beyond the diagnosis of coeliac disease. Pathol Res Pract 2011; 207:538.
35. Du L, Shen J, Kim JJ, et al. Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study. Sci Rep 2016; 6:34305.
36. Vanheel H, Vicario M, Boesmans W, et al. Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural Evaluation. Sci Rep 2018; 8:5383.
37. Kato M, Kephart GM, Talley NJ, et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998; 252:418.
38. DeBrosse CW, Case JW, Putnam PE, et al. Quantity and distribution of eosinophils in the gastrointestinal tract of children. Pediatr Dev Pathol 2006; 9:210.
39. Cirillo C, Bessissow T, Desmet AS, et al. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol 2015; 110:1205.
40. Castillo EJ, Camilleri M, Locke GR, et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004; 2:985.
41. Goodwin RD, Cowles RA, Galea S, Jacobi F. Gastritis and mental disorders. J Psychiatr Res 2013; 47:128.
42. Mak AD, Wu JC, Chan Y, et al. Dyspepsia is strongly associated with major depression and generalised anxiety disorder - a community study. Aliment Pharmacol Ther 2012; 36:800.
43. Koloski NA, Jones M, Kalantar J, et al. The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61:1284.
44. Drossman DA, Talley NJ, Leserman J, et al. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med 1995; 123:782.

45. [Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994; 107:1040.](#)
46. [Bisschops R, Karamanolis G, Arts J, et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 2008; 57:1495.](#)
47. [Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology 2016; 150:1380.](#)
48. [Carbone F, Holvoet L, Tack J. Rome III functional dyspepsia subdivision in PDS and EPS: recognizing postprandial symptoms reduces overlap. Neurogastroenterol Motil 2015; 27:1069.](#)
49. [Quigley EM, Lacy BE. Overlap of functional dyspepsia and GERD--diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol 2013; 10:175.](#)
50. [Lacy BE. Functional dyspepsia and gastroparesis: one disease or two? Am J Gastroenterol 2012; 107:1615.](#)
51. [Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut 2014; 63:1972.](#)
52. [von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2019; 64:480.](#)
53. [Pohl D, Van Oudenhove L, Törnblom H, et al. Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms in Patients With Irritable Bowel Syndrome. Clin Gastroenterol Hepatol 2018; 16:1745.](#)
54. [Lacy BE, Talley NJ, Locke GR 3rd, et al. Review article: current treatment options and management of functional dyspepsia. Aliment Pharmacol Ther 2012; 36:3.](#)
55. [Moayyedi P, Deeks J, Talley NJ, et al. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003; 98:2621.](#)
56. [Mazzoleni LE, Sander GB, Francesconi CF, et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch Intern Med 2011; 171:1929.](#)
57. [Moayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; :CD002096.](#)




58. [Pinto-Sanchez MI, Yuan Y, Hassan A, et al. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev 2017; 11:CD011194.](#)
59. [Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; :CD001960.](#)
60. [Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108:65.](#)
61. [Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93:160.](#)
62. [Lu Y, Chen M, Huang Z, Tang C. Antidepressants in the Treatment of Functional Dyspepsia: A Systematic Review and Meta-Analysis. PLoS One 2016; 11:e0157798.](#)
63. [Wu JC, Cheong PK, Chan YC, et al. A randomized, double-blind, placebo-controlled trial of low dose imipramine for treatment of refractory functional dyspepsia \(FD\) \(abstract #216\). Gastroenterology 2011; 140:S50.](#)
64. [Cheong PK, Ford AC, Cheung CKY, et al. Low-dose imipramine for refractory functional dyspepsia: a randomised, double-blind, placebo-controlled trial. Lancet Gastroenterol Hepatol 2018; 3:837.](#)
65. [Tack J, Ly HG, Carbone F, et al. Efficacy of Mirtazapine in Patients With Functional Dyspepsia and Weight Loss. Clin Gastroenterol Hepatol 2016; 14:385.](#)
66. [Jiang SM, Jia L, Liu J, et al. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol 2016; 22:5260.](#)
67. [Carbone F, Vanuytsel T, Tack J. The effect of mirtazapine on gastric accommodation, gastric sensitivity to distention, and nutrient tolerance in healthy subjects. Neurogastroenterol Motil 2017; 29.](#)
68. [Pittayanon R, Yuan Y, Bollegala NP, et al. Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. Am J Gastroenterol 2019; 114:233.](#)
69. [Soo S, Moayyedi P, Deeks J, et al. Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; :CD002301.](#)
70. [Tack J, Janssen P, Masaoka T, et al. Efficacy of buspirone, a fundus-relaxing drug, in](#)


- [patients with functional dyspepsia. Clin Gastroenterol Hepatol 2012; 10:1239.](#)
71. [Caviglia GP, Sguazzini C, Cisarò F, et al. Gastric emptying and related symptoms in patients treated with buspirone, amitriptyline or clebopride: a "real world" study by 13C-octanoic Acid Breath Test. Minerva Med 2017; 108:489.](#)
  72. [Stein DJ, Bruce Lydiard R, Herman BK, Mandel FS. Impact of gastrointestinal symptoms on response to pregabalin in generalized anxiety disorder: results of a six-study combined analysis. Int Clin Psychopharmacol 2009; 24:126.](#)
  73. [Saito YA, Almazar AE, Tilkes KE, et al. Randomised clinical trial: pregabalin vs placebo for irritable bowel syndrome. Aliment Pharmacol Ther 2019; 49:389.](#)
  74. [Gan Y, Liu H, Yang L, Yang K. Effect of banxiaxixin tang on treatment of functional dyspepsia: a meta-analysis of randomized controlled trials. J Tradit Chin Med 2014; 34:140.](#)
  75. [Lan L, Zeng F, Liu GJ, et al. Acupuncture for functional dyspepsia. Cochrane Database Syst Rev 2014; :CD008487.](#)
  76. [Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol 2004; 2:957.](#)
  77. [Pilichiewicz AN, Horowitz M, Russo A, et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007; 102:1276.](#)
  78. [von Arnim U, Peitz U, Vinson B, et al. STW 5, a phytopharmakon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102:1268.](#)
  79. [Chey WD, Lacy BE, Cash BD, et al. A Novel, Duodenal-Release Formulation of a Combination of Caraway Oil and L-Menthol for the Treatment of Functional Dyspepsia: A Randomized Controlled Trial. Clin Transl Gastroenterol 2019; 10:e00021.](#)
  80. [Duncanson KR, Talley NJ, Walker MM, Burrows TL. Food and functional dyspepsia: a systematic review. J Hum Nutr Diet 2018; 31:390.](#)
  81. [Saito YA, Locke GR 3rd, Weaver AL, et al. Diet and functional gastrointestinal disorders: a population-based case-control study. Am J Gastroenterol 2005; 100:2743.](#)
  82. [Olafsdottir LB, Gudjonsson H, Jonsdottir HH, et al. Natural history of functional](#)

[gastrointestinal disorders: comparison of two longitudinal population-based studies. Dig Liver Dis 2012; 44:211.](#)

Topic 19 Version 38.0

Approach to the evaluation and management of dyspepsia in adults





*H. pylori*: *Helicobacter pylori*.

\* Gastric mucosal biopsies should be obtained at the time of upper gastrointestinal endoscopy to rule out infection with *H. pylori*.

¶ Additional evaluation may be required based on symptoms (eg, abdominal imaging in patients with concurrent jaundice or pain suggestive of a biliary/pancreatic source).

Δ Refer to UpToDate topic reviews.

◇ Patients with continued symptoms of dyspepsia for 3 months with symptom onset at least 6 months before diagnosis and no evidence of structural disease to explain the symptoms should be diagnosed and treated as functional dyspepsia.

§ Eradication of *H. pylori* infection can be confirmed with a urea breath test, stool antigen testing, or upper endoscopy-based testing performed 4 weeks after completion of antibiotic therapy. The choice of test depends on the need for an upper endoscopy (eg, follow-up of bleeding peptic ulcer) and local availability.

*H. pylori* serology should not be used to confirm eradication of *H. pylori*. Refer to UpToDate topic on diagnostic tests for *H. pylori*.

‡ Allow 8 to 12 weeks before reassessing symptomatic response.

‡ For patients with a partial clinical response to a proton pump inhibitor, a tricyclic antidepressant can be initiated as combination therapy with a proton pump inhibitor.

Graphic 115195 Version 3.0

## Rome IV Criteria for Functional Dyspepsia

<b>B1. Functional dyspepsia*</b>
<b>Diagnostic criteria</b> ¶
1. One or more of the following:
a. Bothersome postprandial fullness
b. Bothersome early satiation
c. Bothersome epigastric pain
d. Bothersome epigastric burning
<b>AND</b>
2. No evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms
<b>B1a. Postprandial distress syndrome</b>
<b>Diagnostic criteria</b> ¶
Must include one or both of the following at least three days per week:
1. Bothersome postprandial fullness (ie, severe enough to impact on usual activities)
2. Bothersome early satiation (ie, severe enough to prevent finishing a regular-size meal)
No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy)
<b>Supportive remarks</b>
▪ Postprandial epigastric pain or burning, epigastric bloating, excessive belching, and nausea can also be present
▪ Vomiting warrants consideration of another disorder
▪ Heartburn is not a dyspeptic symptom but may often coexist
▪ Symptoms that are relieved by evacuation of feces or gas should generally not be considered as part of dyspepsia
Other individual digestive symptoms or groups of symptoms, eg, from gastroesophageal reflux disease and the irritable bowel syndrome may coexist with PDS
<b>B1b. Epigastric pain syndrome</b>
<b>Diagnostic criteria</b> ¶
Must include at least one of the following symptoms at least one day a week:
1. Bothersome epigastric pain (ie, severe enough to impact on usual activities)
<b>AND/OR</b>
2. Bothersome epigastric burning (ie, severe enough to impact on usual activities)
No evidence of organic, systemic, or metabolic disease that is likely to explain the symptoms on routine investigations (including at upper endoscopy)
<b>Supportive remarks</b>
1. Pain may be induced by ingestion of a meal, relieved by ingestion of a meal, or may occur while fasting
2. Postprandial epigastric bloating, belching, and nausea can also be present

3. Persistent vomiting likely suggests another disorder
4. Heartburn is not a dyspeptic symptom but may often coexist
5. The pain does not fulfill biliary pain criteria
6. Symptoms that are relieved by evacuation of feces or gas generally should not be considered as part of dyspepsia
Other digestive symptoms (such as from gastroesophageal reflux disease and the irritable bowel syndrome) may coexist with EPS

PDS: postprandial distress syndrome; EPS: epigastric pain syndrome.

\* Must fulfill criteria for PDS and/or EPS.

¶ Criteria fulfilled for the last three months with symptom onset at least six months before diagnosis.

*Original table modified for this publication. Stanghellini V, Chan FKL, Hasler WL, et al. Gastrointestinal disorder. Gastroenterology 2016; 150:1380. Table used with the permission of Elsevier Inc. All rights reserved.*

Graphic 108003 Version 1.0

## Differential diagnosis of dyspepsia

<b>Diagnosis</b>
Functional dyspepsia
<b>Dyspepsia caused by structural or biochemical disease</b>
Peptic ulcer disease
Gastroesophageal reflux disease (GERD)
Biliary pain
Chronic abdominal wall pain
Gastric or esophageal cancer
Gastroparesis
Pancreatitis
Carbohydrate malabsorption
Medications (including potassium supplements, digitalis, iron, theophylline, oral antibiotics [especially ampicillin and erythromycin], nonsteroidal antiinflammatory drugs [NSAIDs], glucocorticoids, niacin, gemfibrozil, narcotics, colchicine, quinidine, estrogens, levodopa)
Infiltrative diseases of the stomach (eg, Crohn disease, sarcoidosis)
Metabolic disturbances (hypercalcemia, hyperkalemia)
Hepatocellular carcinoma
Ischemic bowel disease, celiac artery compression syndrome, superior mesenteric artery syndrome
Systemic disorders (diabetes mellitus, thyroid and parathyroid disorders, connective tissue disease)
Intestinal parasites ( <i>Giardia</i> , <i>Strongyloides</i> )
Abdominal cancer, especially pancreatic cancer

Adapted from:

1. Talley NJ, Silverstein MD, Agrus L, et al. American Gastroenterological Association (AGA) technical review: evaluation of dyspepsia. *Gastroenterology* 1998; 114:582.
2. Fisher RS, Parkman HP. Management of nonulcer dyspepsia. *N Engl J Med* 1998; 339:1376.

Graphic 90590 Version 10.0



## Contributor Disclosures

**George F Longstreth, MD** Nothing to disclose **Brian E Lacy, MD, PhD** Nothing to disclose **Nicholas J Talley, MD, PhD** Employment: University of Newcastle [PVC Global Research]; John Hunter Hospital [Senior Staff Specialist in gastroenterology]; Medical Journal of Australia [Editor-In-Chief]. Patent Holder: Biomarkers of irritable bowel syndrome [Irritable bowel syndrome]; Licensing Questionnaires [Mayo Clinic Talley Bowel Disease Questionnaire - Mayo Dysphagia Questionnaire (Nepean Dyspepsia Index)]; Nestec European Patent [Application 127353589; Nanotechnology]; Singapore 'Provisional' Patent [NTU Ref TD/129/17 "Microbiota Modulation Of BDNF Tissue Repair Pathway"]. Grant/Research/Clinical Trial Support: Commonwealth Labs [IBS (diagnostic blood test)]; VN National Science Challenge [Research funding for IBS]. Consultant/Advisory Boards: Adelphi Values [Functional dyspepsia (Patient-reported outcome measures)]; Viscera Labs [Bile acid sequestrant]; twoXAR [IBS]; Anantara Lifesciences [IBS, IBD (Dietary supplement)]; Avrio [Gastroenterology (OTC drugs)]; Censa [Diabetic gastroparesis epidemiology]; Sanofi [Probiotic product (Bacillus clausii)]; Pfizer [IBS (OTC drugs in gastroenterology)]; Planet Innovation [Gastroenterology (Gas capsule)]; Takeda [Gastroparesis (TAK906)]; Allakos [Gastric eosinophilic disease (AK002)]; Progenity Inc, San Diego [SIBO (Intestinal capsule device)]; IM HealthScience [IBS, FD (Peppermint oil)]. Other Financial Interest: IM Health Science [Medicine, clinical skills]. **Shilpa Grover, MD, MPH, AGAF** Nothing to disclose

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

[Conflict of interest policy](#)